A new analysis from the randomised phase 3 NRG/RTOG 0815 trial suggests that the Decipher genomic classifier may do more than estimate prognosis: it may help predict which men with intermediate-risk prostate cancer actually benefit from adding short-term androgen deprivation therapy to dose-escalated radiotherapy. Researchers analysed tumour samples from 395 men, with a median follow-up […]
A new study suggests that ATM alterations could identify a subgroup of metastatic castration-resistant prostate cancer particularly likely to benefit from 177Lu-PSMA-617 (Pluvicto). The retrospective analysis included 205 men with mCRPC treated with Lu-177-PSMA-617 between 2022 and 2026, all of whom had next-generation DNA sequencing available. ATM alterations were present in 12.7% of patients and […]
A new analysis of the phase 3 ARCHES trial suggests that a simple clinical model may help predict which men with metastatic hormone-sensitive prostate cancer are most likely to achieve a very deep PSA response after starting treatment with an androgen-receptor pathway inhibitor. The model, called NADIR, was designed to estimate the probability of reaching […]
Prostate cancer that develops neuroendocrine features is commonly associated with loss of androgen-receptor dependence and reduced PSMA expression, potentially making PSMA-targeted treatments less useful. A new dual-tracer imaging study suggests that the reality may be considerably more complicated. Researchers retrospectively examined eight men with metastatic castration-resistant prostate cancer who were suspected of developing treatment-emergent neuroendocrine […]
A new retrospective study with a 10-year follow-up suggests that some men with prostate cancer recurring only in lymph nodes may achieve prolonged disease control using PET-directed radiotherapy combined with temporary androgen deprivation therapy (ADT). The retrospective study included 93 men with hormone-sensitive prostate cancer that had returned in pelvic and/or para-aortic lymph nodes after […]
For men with metastatic prostate cancer, the current standard is continuous androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI) such as abiraterone, enzalutamide, apalutamide, or darolutamide. This approach improves survival but comes with substantial clinical and financial toxicity: fatigue, metabolic changes, sexual dysfunction, bone loss, cardiovascular risk, and long‑term treatment costs. The […]
A retrospective analysis from the Oxford GPS-ProMPT study provides further evidence that genomic profiling can reveal which prostate cancers are truly aggressive and which are not, even when clinical features suggest otherwise. The study evaluated the 17-gene Genomic Prostate Score (GPS mdx) in 409 patients managed with active surveillance, radical prostatectomy, or radiotherapy with androgen […]
A regional retrospective study covering 2011 to 2025 suggests that a more intensive radiotherapy strategy may improve survival in selected patients with prostate cancer and bone metastases. The analysis included 246 consecutive men who received 347 radiotherapy courses and asked whether treating bone lesions more aggressively, together with prostate-directed radiotherapy, could translate into longer overall […]
Using data from the international ARON-3 real-world study, investigators performed a retrospective head-to-head comparison of darolutamide- and abiraterone-based triplet therapy in patients with metastatic hormone-sensitive prostate cancer. The comparison included 247 patients treated with darolutamide plus docetaxel plus androgen deprivation therapy or abiraterone plus docetaxel plus androgen deprivation therapy across 37 institutions in 14 countries. […]
A recent study, published on Nature, looked at a question that matters just as much as prostate cancer risk: why do some tumors stay quiet while others become life-threatening after diagnosis? The researchers searched for genes whose activity might be linked to survival, not just to the chance of developing the disease. To do this, […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy